Vericel (VCEL) Competitors $45.70 +1.88 (+4.29%) Closing price 04:00 PM EasternExtended Trading$45.70 +0.00 (+0.01%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VCEL vs. BPMC, ROIV, RVMD, BBIO, ELAN, VRNA, LEGN, TGTX, GRFS, and LNTHShould you be buying Vericel stock or one of its competitors? The main competitors of Vericel include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma (VRNA), Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Vericel vs. Blueprint Medicines Roivant Sciences Revolution Medicines BridgeBio Pharma Elanco Animal Health Verona Pharma Legend Biotech TG Therapeutics Grifols Lantheus Vericel (NASDAQ:VCEL) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment. Which has preferable earnings & valuation, VCEL or BPMC? Vericel has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$238.54M9.64-$3.18M$0.031,523.17Blueprint Medicines$562.12M14.70-$67.09M-$2.47-51.79 Does the MarketBeat Community believe in VCEL or BPMC? Blueprint Medicines received 198 more outperform votes than Vericel when rated by MarketBeat users. Likewise, 66.99% of users gave Blueprint Medicines an outperform vote while only 61.81% of users gave Vericel an outperform vote. CompanyUnderperformOutperformVericelOutperform Votes35661.81% Underperform Votes22038.19% Blueprint MedicinesOutperform Votes55466.99% Underperform Votes27333.01% Do analysts prefer VCEL or BPMC? Vericel presently has a consensus target price of $61.14, suggesting a potential upside of 33.81%. Blueprint Medicines has a consensus target price of $129.35, suggesting a potential upside of 1.12%. Given Vericel's stronger consensus rating and higher probable upside, research analysts plainly believe Vericel is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Blueprint Medicines 0 Sell rating(s) 16 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.32 Is VCEL or BPMC more profitable? Vericel has a net margin of 1.56% compared to Blueprint Medicines' net margin of -13.19%. Vericel's return on equity of 1.48% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Vericel1.56% 1.48% 0.96% Blueprint Medicines -13.19%-77.49%-20.84% Which has more volatility & risk, VCEL or BPMC? Vericel has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Does the media prefer VCEL or BPMC? In the previous week, Blueprint Medicines had 30 more articles in the media than Vericel. MarketBeat recorded 36 mentions for Blueprint Medicines and 6 mentions for Vericel. Vericel's average media sentiment score of 1.65 beat Blueprint Medicines' score of 0.23 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Blueprint Medicines 10 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryVericel beats Blueprint Medicines on 11 of the 17 factors compared between the two stocks. Get Vericel News Delivered to You Automatically Sign up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCEL vs. The Competition Export to ExcelMetricVericelBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.28B$3.12B$5.56B$8.64BDividend YieldN/A1.59%5.27%4.19%P/E Ratio755.0933.6327.3020.18Price / Sales9.56488.11415.29164.91Price / Cash3,081.95168.6838.2534.64Price / Book9.583.507.174.73Net Income-$3.18M-$72.35M$3.23B$248.08M7 Day Performance9.01%13.96%6.81%4.47%1 Month Performance8.59%28.03%15.59%10.83%1 Year Performance4.10%-14.71%32.77%15.09% Vericel Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCELVericel3.132 of 5 stars$45.70+4.3%$61.14+33.8%-1.3%$2.30B$238.54M761.79300Positive NewsBPMCBlueprint Medicines0.9112 of 5 stars$127.97+0.1%$129.35+1.1%+23.8%$8.26B$562.12M-118.49640High Trading VolumeROIVRoivant Sciences2.3488 of 5 stars$11.08-1.3%$17.50+57.9%+5.8%$7.91B$29.05M-73.86860RVMDRevolution Medicines3.8814 of 5 stars$40.58-1.2%$67.08+65.3%+0.6%$7.56B$742,000.00-11.30250BBIOBridgeBio Pharma4.5361 of 5 stars$39.03+1.1%$57.36+47.0%+44.3%$7.41B$127.42M-13.69400Analyst UpgradeGap UpELANElanco Animal Health0.9412 of 5 stars$13.94+0.3%$15.17+8.8%-23.4%$6.92B$4.43B34.859,800Positive NewsVRNAVerona Pharma1.7411 of 5 stars$84.64+0.4%$82.13-3.0%+597.8%$6.86B$118.54M-44.0830LEGNLegend Biotech3.3191 of 5 stars$34.78-0.6%$76.20+119.1%-23.7%$6.39B$728.30M-36.611,070Analyst RevisionTGTXTG Therapeutics3.1447 of 5 stars$39.84-0.5%$40.80+2.4%+151.4%$6.32B$386.39M-398.36290Analyst RevisionGRFSGrifols3.1206 of 5 stars$8.83+0.1%N/A+22.0%$6.07B$7.21B7.5526,300LNTHLantheus4.5695 of 5 stars$83.22+2.0%$132.67+59.4%+4.2%$5.76B$1.54B13.85700 Related Companies and Tools Related Companies BPMC Competitors ROIV Competitors RVMD Competitors BBIO Competitors ELAN Competitors VRNA Competitors LEGN Competitors TGTX Competitors GRFS Competitors LNTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCEL) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
